Effect of Metformin vs Placebo on weight and metabolic factors in NCIC CTG MA.32

Journal of the National Cancer Institute

Volumn 107, Issue 3, 2015, Pages

  Goodwin, Pamela J ^a   Parulekar, Wendy R ^b   Gelmon, Karen A ^c   Shepherd, Lois E ^b   Ligibel, Jennifer A ^d   Hershman, Dawn L ^e   Rastogi, Priya ^f   Mayer, Ingrid A ^g   Hobday, Timothy J ^h   Lemieux, Julie ⁱ   Thompson, Alastair M ^j   Pritchard, Kathleen I ^k   Whelan, Timothy J ^l   Mukherjee, Som D ^l   Chalchal, Haji I ^m   Oja, Conrad D ⁿ   Tonkin, Katia S ^c,o   Bernstein, Vanessa ^p   Chen, Bingshu E ^b   Stambolic, Vuk ^p  

^a MOUNT SINAI HOSPITAL   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d HARVARD MEDICAL SCHOOL   (United States)

^e NewYork Presbyterian Hospital   (United States)

^f UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^h Mayo Clinic   (United States)

ⁱ Université Laval   (Canada)

^j National Cancer Research Network Coordinating Centre   (United Kingdom)

^k DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^l MCMASTER UNIVERSITY   (Canada)

^m Allan Blair Cancer Centre   (Canada)

ⁿ BRITISH COLUMBIA CANCER AGENCY   (Canada)

^o UNIVERSITY OF ALBERTA   (Canada)

^p UNIVERSITY HEALTH NETWORK   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ESTROGEN RECEPTOR; GLUCOSE; INSULIN; LEPTIN; METFORMIN; PLACEBO; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SURGERY; CANCER SURVIVAL; DIET RESTRICTION; DISEASE FREE SURVIVAL; EARLY CANCER; FEMALE; GLUCOSE ASSAY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MASTECTOMY; METABOLIC PARAMETERS; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; UNDERWEIGHT;

EID: 84930404106     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv006     Document Type: Article

References (20)

1. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and metaanalysis. Breast Cancer Res Treat. 2010;123(3):627-635.
2. Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002;20(1):42-51.
3. Goodwin PJ, Ennis M, Pritchard KI, et al. Insulin-and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. J Clin Oncol. 2012;30(2):164-171.
4. Pasanisi P, Berrino F, De PM, Venturelli E, Mastroianni A, Panico S. Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer. 2006;119(1):236-238.
5. Duggan C, Irwin ML, Xiao L, et al. Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol. 2011;29(1):32-39.
6. Emaus A, Veierod MB, Tretli S, et al. Metabolic profile, physical activity, and mortality in breast cancer patients. Breast Cancer Res Treat. 2010;121(3):651-660.
7. Pritchard KI, Shepherd LE, Chapman JA, et al. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. J Clin Oncol. 2011;29(29):3869-3876.
8. Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG. Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer. 2008;8(6):501-505.
9. Hadad S, Iwamoto T, Jordan L, et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat. 2011;128(3):783-794.
10. Bonanni B, Puntoni M, Cazzaniga M, et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol. 2012;30(21):2593-2600.
11. Niraula S, Dowling RJ, Ennis M, et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat. 2012;135(3):821-830.
12. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23(1):57-63.
13. Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med. 2008;121(2):149-157.
14. Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol. 2012;48(3):R31-R43.
15. Goodwin PJ, Ennis M, Fantus IG, et al. Is leptin a mediator of adverse prognostic effects of obesity in breast cancer? J Clin Oncol. 2005;23(25):6037-6042.
16. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer. 2011;11(12):886-895.
17. Shu Y, Brown C, Castro BA, et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharm Therapeut. 2008;83(2):273-280.
18. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metabolism. 2005;1(1):15-25.
19. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8):1167-1174.
20. El-Mir MY, Nogueira V, Fontaine E, Av?et N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex 1. J Biol Chem. 2000;275(1):223-228.